What does it mean when a major medical body elevates a compound to first-line status? In late 2022 the American College of Physicians issued updated guidance on pharmacologic interventions for weight loss. Semaglutide appeared alongside behavioral therapy as a recommended first-line option for adults with obesity. The shift matters because first-line designation changes how physicians think about intervention sequencing. It also raises questions for anyone using or considering semaglutide in a research or self-directed context. Does the recommendation apply to all patient profiles? What does the evidence actually show? And where do other metabolic peptides fit now that semaglutide occupies center stage?
What the ACP guideline actually says
The American College of Physicians reviewed trials spanning behavioral interventions and pharmacologic agents. Their conclusion was straightforward. Adults with a body mass index of 30 or higher should be offered weight-management counseling. If counseling alone does not produce clinically meaningful loss, pharmacotherapy should be considered. Semaglutide was named explicitly as a first-line agent.
The recommendation rests on data from the STEP trial series. These studies enrolled thousands of participants across multiple continents. Average weight loss at 68 weeks ranged from 12 to 15 percent of baseline body weight. Placebo groups lost roughly 2 to 3 percent. The difference was consistent across subgroups defined by sex, age, and baseline metabolic markers.
Published research on semaglutide consistently shows dose-dependent effects. Higher weekly doses produce greater reductions in body weight and waist circumference. Adverse events are also dose-dependent. Nausea and gastrointestinal discomfort appear in approximately 40 percent of participants at the 2.4 mg weekly dose. Most events resolve within weeks. Discontinuation rates hover near 7 percent.
The ACP stopped short of recommending semaglutide for everyone. The guideline emphasizes shared decision-making. Clinicians are instructed to discuss potential benefits, known risks, and cost. Insurance coverage remains inconsistent. Out-of-pocket expense can exceed $1,000 per month in the United States.
How semaglutide compares to earlier metabolic peptides
Semaglutide is a glucagon-like peptide-1 receptor agonist. It mimics a gut hormone that regulates insulin secretion and appetite. The compound has a half-life of approximately one week. This allows once-weekly subcutaneous administration. Earlier GLP-1 agonists required daily dosing and produced smaller reductions in body weight.
AOD-9604 represents a different mechanistic class. It is a fragment of human growth hormone modified to retain lipolytic activity without affecting blood glucose. Animal studies suggest AOD-9604 stimulates fat breakdown in adipose tissue. Human trials have been smaller and less consistent. One published trial in obese adults found modest reductions in body weight over 12 weeks. Another found no significant difference from placebo.
The evidence base for AOD-9604 remains thin compared to semaglutide. No large-scale randomized controlled trials have been published in the past decade. Regulatory agencies have not approved the peptide for weight loss. Some researchers continue to investigate its potential as an adjunct to caloric restriction.
Hexarelin and MOTS-c occupy adjacent territory. Hexarelin is a growth hormone secretagogue. MOTS-c is a mitochondrial-derived peptide implicated in metabolic regulation. Both have shown effects on body composition in animal models. Human data is sparse. Side-effect and adverse-event data for many peptides is sparse. Absence of reported harm does not equate to absence of risk.
What the guidelines mean for protocol design
First-line designation changes the calculus for anyone designing a weight-loss protocol. It signals that semaglutide has crossed a threshold of evidence and safety that earlier agents have not. The ACP reviewed head-to-head trials comparing semaglutide to older GLP-1 agonists. Semaglutide produced greater weight loss in every comparison.
Does this mean other peptides have no role? Not necessarily. Some practitioners layer metabolic peptides in sequence or combination. A common approach begins with semaglutide to drive initial weight loss. Once a plateau is reached, adjuncts like CJC-1295 or MOTS-c are introduced to preserve lean mass or enhance mitochondrial function. Published research on combination protocols is limited. Most data comes from case series rather than controlled trials.
Tirzepatide represents a newer option. It is a dual GIP and GLP-1 agonist. Head-to-head trials show tirzepatide produces slightly greater weight loss than semaglutide. Average reductions at 72 weeks approach 20 percent of baseline body weight. Gastrointestinal side effects are similar. Tirzepatide has not yet been included in ACP guidelines because the recommendation predates its widespread availability.
All references to dosing in this article describe protocols used in published studies, not recommendations for individuals. The literature on peptide stacking is mostly observational. Controlled trials comparing monotherapy to combination regimens are rare. This leaves protocol designers in a gray zone. They must weigh mechanistic plausibility against the absence of safety data.
Who benefits most from semaglutide under the new guidelines
The ACP guideline does not specify patient subtypes. It applies to adults with a BMI of 30 or higher. But published subgroup analyses reveal variation in response. Women tend to lose slightly more weight than men at equivalent doses. Participants with higher baseline insulin resistance show greater improvements in glycemic markers. Age does not predict magnitude of weight loss in most studies.
Comorbidity status matters. Research examining how sex and comorbidity influence semaglutide outcomes suggests that individuals with type 2 diabetes experience dual benefits. They lose weight and achieve better glucose control. Those without diabetes lose weight but do not see metabolic improvements beyond what weight loss itself confers.
Cardiovascular risk is another consideration. Semaglutide reduces major adverse cardiovascular events in people with established heart disease. The effect appears independent of weight loss. This makes the compound particularly attractive for obese individuals with a history of myocardial infarction or stroke.
Psychiatric comorbidity complicates the picture. Some studies excluded participants with active eating disorders. Binge eating disorder is common in obesity. Whether semaglutide helps or harms individuals with binge eating remains unclear. The peptide reduces appetite. It does not address the psychological drivers of disordered eating. Clinicians are advised to screen for eating pathology before initiating treatment.
Open questions the guidelines leave unanswered
First-line status does not mean all questions are settled. Duration of treatment remains contentious. Most trials ran for 68 to 72 weeks. Weight regain after discontinuation is common. One study found participants regained two-thirds of lost weight within a year of stopping semaglutide. This suggests indefinite use may be necessary to maintain results.
Long-term safety data beyond two years is limited. Rodent studies raised concerns about thyroid C-cell tumors. Human epidemiologic data has not confirmed this risk. Regulatory agencies require a black-box warning. Individuals with a personal or family history of medullary thyroid carcinoma are advised to avoid GLP-1 agonists.
Cost-effectiveness analyses vary by healthcare system. In countries with universal coverage, semaglutide appears cost-effective when quality-adjusted life years are factored in. In the United States, where patients often bear significant out-of-pocket costs, the calculus shifts. Some insurers cover the compound only for type 2 diabetes, not obesity.
The role of adjunct peptides remains speculative. Can AOD-9604 or MOTS-c enhance fat loss when added to semaglutide? Do growth hormone secretagogues like hexarelin preserve muscle during caloric deficit? These questions lack definitive answers. The literature on combination protocols is mostly anecdotal. Controlled trials are needed. Until then, practitioners operate on mechanistic reasoning and clinical observation.
What happens when semaglutide stops working? Some individuals plateau after six months despite dose escalation. Is this true resistance or a reflection of adaptive thermogenesis? And if resistance develops, does switching to tirzepatide restore response?